To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's medical history, family history of OAG or OHT, concomitant systemic treatment with beta-blockers, etiology, IOP at baseline, corneal thickness, compliance, and adverse events).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
396
A positive response defined as an additional IOP reduction over 10% after 12 weeks of treatment in the intent to treat (ITT) population.
Time frame: after 12 weeks of treatment
Absolute and relative IOP change after 4 and 12 weeks of treatment
Time frame: week 4 and 12
Percentage of patients achieving a target IOP value: under 18 mmHg and under 16 mmHg after 12 weeks of treatment,
Time frame: week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
D0 and D84
Pfizer Investigational Site
Agen, France
Pfizer Investigational Site
Amboise, France
Pfizer Investigational Site
Amiens, France
Pfizer Investigational Site
Andrésy, France
Pfizer Investigational Site
Asnières-sur-Seine, France
Pfizer Investigational Site
Aubière, France
Pfizer Investigational Site
Aurillac, France
Pfizer Investigational Site
Belfort, France
Pfizer Investigational Site
Besançon, France
Pfizer Investigational Site
Béziers, France
...and 92 more locations